Spero Therapeutics, Inc. (SPRO) stock
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.00−0.00 (-0.01%)
Close on Nov 13, 2026Market cap $58.23MP/E –Yield –
Spero Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Spero Therapeutics's total assets was $110.03M at Sep 30, 2026. For fiscal 2025 it was $68.92M, down 37.7% from the year before. The highest annual figure on record is $182.39M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.92M | -37.7% |
| FY2024 | Dec 31, 2024 | $110.54M | -39.4% |
| FY2023 | Dec 31, 2023 | $182.39M | +46.1% |
| FY2022 | Dec 31, 2022 | $124.80M | -27.0% |
| FY2021 | Dec 31, 2021 | $171.07M | +11.5% |
| FY2020 | Dec 31, 2020 | $153.45M | +44.6% |
| FY2019 | Dec 31, 2019 | $106.10M | -17.8% |
| FY2018 | Dec 31, 2018 | $129.01M | +38.0% |
| FY2017 | Dec 31, 2017 | $93.48M | +578.8% |
| FY2016 | Dec 31, 2016 | $13.77M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $110.03M | +103.1% |
| Q2 FY2026 | Jun 30, 2026 | $52.77M | -15.1% |
| Q1 FY2026 | Mar 31, 2026 | $59.02M | -24.0% |
| Q4 FY2025 | Dec 31, 2025 | $68.92M | -37.7% |
| Q3 FY2025 | Sep 30, 2025 | $54.17M | -59.9% |
| Q2 FY2025 | Jun 30, 2025 | $62.12M | -58.6% |
| Q1 FY2025 | Mar 31, 2025 | $77.71M | -53.7% |
| Q4 FY2024 | Dec 31, 2024 | $110.54M | -39.4% |
| Q3 FY2024 | Sep 30, 2024 | $135.16M | +26.2% |
| Q2 FY2024 | Jun 30, 2024 | $149.88M | +51.6% |
| Q1 FY2024 | Mar 31, 2024 | $167.70M | +49.0% |
| Q4 FY2023 | Dec 31, 2023 | $182.39M | +46.1% |
| Q3 FY2023 | Sep 30, 2023 | $107.10M | +66.1% |
| Q2 FY2023 | Jun 30, 2023 | $98.89M | +55.4% |
| Q1 FY2023 | Mar 31, 2023 | $112.55M | -22.8% |
| Q4 FY2022 | Dec 31, 2022 | $124.80M | -27.0% |
| Q3 FY2022 | Sep 30, 2022 | $64.48M | -55.4% |
| Q2 FY2022 | Jun 30, 2022 | $63.63M | -46.8% |
| Q1 FY2022 | Mar 31, 2022 | $145.83M | +1.7% |
| Q4 FY2021 | Dec 31, 2021 | $171.07M | +11.5% |
| Q3 FY2021 | Sep 30, 2021 | $144.69M | -7.9% |
| Q2 FY2021 | Jun 30, 2021 | $119.59M | +22.6% |
| Q1 FY2021 | Mar 31, 2021 | $143.44M | +30.5% |
| Q4 FY2020 | Dec 31, 2020 | $153.45M | +44.6% |
| Q3 FY2020 | Sep 30, 2020 | $157.04M | +39.6% |
| Q2 FY2020 | Jun 30, 2020 | $97.55M | -20.4% |
| Q1 FY2020 | Mar 31, 2020 | $109.89M | -11.8% |
| Q4 FY2019 | Dec 31, 2019 | $106.10M | -17.8% |
| Q3 FY2019 | Sep 30, 2019 | $112.51M | -17.3% |
| Q2 FY2019 | Jun 30, 2019 | $122.49M | +68.7% |
| Q1 FY2019 | Mar 31, 2019 | $124.65M | +53.8% |
| Q4 FY2018 | Dec 31, 2018 | $129.01M | +38.0% |
| Q3 FY2018 | Sep 30, 2018 | $136.12M | +331.4% |
| Q2 FY2018 | Jun 30, 2018 | $72.59M | +427.1% |
| Q1 FY2018 | Mar 31, 2018 | $81.06M | – |
| Q4 FY2017 | Dec 31, 2017 | $93.48M | – |
| Q3 FY2017 | Sep 30, 2017 | $31.55M | – |
| Q4 FY2016 | Dec 31, 2016 | $13.77M | – |
See a number that looks wrong?